The Rotten-Egg Burp Is the Most-Searched Zepbound Side Effect. Its Own Label Never Mentions It.

A gap you can check yourself

Zepbound's prescribing information runs to about 820 kilobytes. Wegovy's runs to about 943. Between them they catalog vomiting rates, gallbladder events, thyroid tumors in rodents, what to do before anesthesia, and how long to wait after a missed dose.

Neither document contains the word sulfur. Or sulphur. Or rotten, or egg, or odor, or smell.

What they do contain is eructation — the clinical term for belching, which appears five times in the Wegovy label and twice in Zepbound's, plus a single plain-English "belch" in each. The belch is recorded. The smell is not.

That absence is the most honest starting point for this subject, because it explains why the answers women find are so unsatisfying. There is no official description of the thing being asked about. The regulatory documents note that people burp more. The part that makes it memorable — that it smells like a boiled egg left out — exists almost entirely in patient accounts.

What the labels do say, and the surprise inside it

If you assume the newer, stronger-seeming drug produces more of everything, the numbers say otherwise.

Two things in that table are worth sitting with.

Semaglutide is the bigger belcher. Wegovy's rate is 7% against Zepbound's 5% at the top dose — and against a placebo arm that reported under 1%, making it the largest fold increase in Wegovy's entire gastrointestinal list.

On Zepbound it stops climbing. Four percent at 5 mg, five percent at 10 mg, five percent at 15 mg. Whatever produces the belching appears to saturate early. Nausea does not behave this way in the same table — it moves 25%, 29%, 28% — so this is not simply "everything gets worse as you titrate."

There is a second oddity in Zepbound's table that almost nobody mentions, and it runs against the entire folk understanding of these drugs. Constipation goes down as the dose goes up: 17% at 5 mg, 14% at 10 mg, 11% at 15 mg. If you have been told the higher doses are uniformly harder on the gut, the drug's own trials disagree.

Why it smells the way it does

Here the honest answer is that the mechanism is inferred rather than demonstrated, and it is worth marking the difference clearly, because every page you will read states it as fact.

Sulfur burps in general — not specifically on these drugs — are attributed to hydrogen sulfide gas produced when gut bacteria break down sulfur-containing proteins. The rotten-egg association is not poetic; hydrogen sulfide is the compound that gives rotten eggs their smell.

The plausible chain on a GLP-1 runs: food moves through the upper gut more slowly, protein sits longer with the bacteria that ferment it, more hydrogen sulfide is produced, and it comes back up rather than continuing down.

No study has demonstrated that chain in people taking a GLP-1. Not a small one. The broad 2024 review of gastrointestinal effects of these drugs in The Lancet Gastroenterology & Hepatology sets out mechanisms and management for the class, and notes how much of the management guidance rests on clinical experience rather than trial evidence². That caveat applies here in full.

One adjacent finding is worth knowing precisely because it is so often overstated. A 2025 cohort study matched 216,173 adults starting a GLP-1 or dual GLP-1/GIP agonist against an equal number on other second-line diabetes agents and found more confirmed small intestinal bacterial overgrowth on the GLP-1 drugs — hazard ratio 2.14. But the rates being doubled are 0.177 against 0.083 per 1,000 patient-years, fewer than two diagnoses per ten thousand patient-years, and the long-term analysis did not reach significance³. Bacterial overgrowth is a real phenomenon and it is not the explanation for the burps most women are having.

What women actually say about it

The published account closest to lived experience is a qualitative study in JAMA Network Open, which conducted semistructured video interviews with 30 people across 15 US states — 19 of them women, mean age 54 — and analyzed the transcripts without a predetermined framework¹.

Several of its themes land directly on this subject, and none of them is about belching specifically.

Participants described a wide spectrum of adverse effects, and a willingness to endure substantial ones to stay on treatment¹. That is the honest frame for sulfur burps: not a reason most women stop, but a genuine daily cost that gets absorbed silently.

Participants also reported that information and clinical support were essential but highly variable¹. Which is exactly what produces a 2,100-searches-a-month question with no authoritative answer behind it. Women are not searching this because it is trivial. They are searching it because they asked and got nothing, or did not feel able to ask at all.

And that is the social shape of this particular side effect. Nausea is sayable. Constipation is sayable, barely. A burp that clears a room is not something most women will raise in a seven-minute appointment, and it is not something the appointment tends to ask about.

What tends to help

None of this has been tested against GLP-1 belching specifically. It is mechanism-led, and it is fair to label it as such.

Look at the protein first. If the working explanation is sulfur-containing protein fermenting, the highest-sulfur foods are the obvious lever: eggs, red meat, and the cruciferous vegetables — broccoli, cauliflower, cabbage, Brussels sprouts. This is genuinely awkward advice on a drug where you are being told to prioritize protein, and pretending otherwise is not useful. The workable version is usually shifting which protein rather than reducing it.

Watch the whey. Protein shakes are the default solution to a suppressed appetite, and whey is a common trigger. Switching the source is a cheap experiment.

Slow the meal down. Air swallowed while eating fast is a straightforward contributor, and eating fast is what happens standing at a counter.

Reconsider the fizzy water. It is what most women switch to when food stops appealing, and it is a direct source of gas.

Treat the constipation. It is the largest gastrointestinal change on both labels, and a backed-up bowel pushes gas upward.

If the burping arrives with a dose increase and is still there three weeks later, that is information about the pace. The instruction in both labels for a dose that is not tolerated is the same: consider delaying the escalation rather than pushing through it.

What would change this page

A single study characterizing the gas — measuring whether hydrogen sulfide is actually elevated in people taking these drugs, and whether it tracks with dose.

That study does not exist. Until it does, the most-searched question about this drug class is being answered by inference from general gastroenterology and by women comparing notes with each other, which is a reasonable thing to do and is not the same as knowing.